MRI reveals disappearance of hemorrhagic signal and development of necrotic changes Pain reduced from a median of 7 on a scale of 0 - 10 to a median of 1, with some patients reporting 0 Five doctors ...

Dedicated CIRSE focus session on the breast shows the growing interest from interventional radiologists to expand their practice to include care for breast cancer patients CAESAREA, Israel, Sept. 22, ...

CAESAREA, Israel, Feb. 15, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that ...

CAESAREA, Israel, March 18, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that ...

IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive ...

The MarketWatch News Department was not involved in the creation of this content. Breast surgeon, Professor Eisuke Fukuma, a highly regarded cryoablation expert & ProSense(R) user at Kameda Medical ...

CAESAREA, Israel, Aug. 21, 2023 /PRNewswire/ -- IceCure Medical LTD. (ICCM) (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology ...

Abstracts presented include 3 studies involving 263 patients, adding to a growing body of evidence across diverse patient populations supporting broader adoption of ProSense® CAESAREA, Israel, Dec. 10 ...

CAESAREA, Israel, Nov. 8, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense ® ...

CAESAREA, Israel, March 20, 2019 /PRNewswire/ -- IceCure Medical, developer of the next generation liquid-nitrogen-based cryoablation technology to treat tumors by freezing, today announced promising ...